Stock APLS APELLIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Apellis Pharmaceuticals, Inc.

Equities

APLS

US03753U1060

Real-time Estimate Cboe BZX
Other stock markets
 11:34:17 2024-05-28 am EDT 		5-day change 1st Jan Change
40.16 USD -1.12% Intraday chart for Apellis Pharmaceuticals, Inc. -5.29% -32.66%
May. 24 Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases MT
May. 24 Apellis Pharmaceuticals, Inc. Announces Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases
MT
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
GL
Apellis Pharmaceuticals, Inc. Announces Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
CI
Wells Fargo Adjusts Price Target on Apellis Pharmaceuticals to $48 From $57, Maintains Equal-Weight Rating
MT
Transcript : Apellis Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:00 AM
Apellis Pharmaceuticals Enters Into Senior Secured Credit Facility With Sixth Street
MT
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
GL
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
CI
Apellis Pharmaceuticals Insider Sold Shares Worth $3,341,848, According to a Recent SEC Filing
MT
UBS Adjusts Price Target on Apellis Pharmaceuticals to $85 From $89, Maintains Buy Rating
MT
Wedbush Adjusts Price Target on Apellis Pharmaceuticals to $50 From $57, Maintains Neutral Rating
MT
Apellis Pharmaceuticals : First Quarter 2024 Earnings Presentation
PU
Transcript : Apellis Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024
Apellis Pharmaceuticals Q1 Net Loss Narrows, Revenue Rises
MT
Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q1 Revenue $172.3M
MT
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
GL
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
GL
Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
GL
Mizuho Securities Cuts Price Target on Apellis Pharmaceuticals to $52 From $60, Maintains Neutral Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. APLS Stock
  4. News Apellis Pharmaceuticals, Inc.